Skip to main content
Figure 5 | Molecular Cancer

Figure 5

From: Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-κB signaling and depleting Bcr-Abl

Figure 5

Pristimerin inhibits growth of imatinib-resistant CML cells in vitro and in vivo. (A) The indicated 5 lines of CML cells were exposed to escalating concentrations of pristimerin for 72 hours, cell viability was measured by MTS assay. (B) Clonogenicity of CML cells in soft agar was inhibited by pristimerin in a dose-dependent manner. Error bars represent SE. (C, D, E) Pristimerin inhibited the growth of xenografted imatinib-resistant CML cells in a nude mouse model. (C) The growth curves of subcutaneous xenografts of KBM5-T315I cells. Nude mice bearing KBM5-T315I xenograft tumors received intratumoral injection with either 50 μL vehicle [30% Cremophor EL/ethanol (4:1), 70% PBS] or 1.0 mg/kg pristimerin in vehicle daily during days 6-19 after inoculation of KBM5-T315I cells. The estimated tumor volume is plotted versus time (C). Points, mean; Error bars, SE. (D) Weights of tumors dissected on day 19 post-inoculation. Columns, mean; error bars, SE. *** indicates P < 0.0001, Student's t test. Representative tumors removed from mice of each group. (E) Immnunohistochemical analysis with anti-c-Abl and H & E staining of xenograft tissues from mice sacrificed 19 days after tumor inoculation.

Back to article page

Molecular Cancer

ISSN: 1476-4598